Tuberculosis medicines for children in Europe: an unmet medical need
Authors:
Open Access
- 8 June 2023
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Abstract
The availability of first-line medicines for the treatment of drug-susceptible tuberculosis (TB) is inconsistent across European countries. This is particularly worrisome for child-friendly medicines. There are reported examples of physicians being forced to adapt and/or combine formulations intended for adults to treat children with TB. Reduced compliance, unknown effects on treatment outcomes and unpredictable toxicity are potential consequences of resorting to these suboptimal treatment options. Furthermore, the use of these alternatives may increase the risk of drug-resistant TB. This study analysed the availability and use of TB medicines in the European Union (EU)/European Economic Area, with a particular focus on child-friendly formulations. We sought to carry out a full review of the situation by means of a survey involving the EU regulatory network. Countries were asked to confirm marketing status of anti-drug-susceptible-TB medicines, ways used to overcome their absence in their territory and the general difficulties they face to treat children with TB. Results confirmed that rifampicin suspension is the only child-friendly formulation available in Europe, approved in just 10 member states. Overall, 24 countries out of 30 considered the lack of adequate drug-susceptible TB medicines an unmet medical need. To overcome this, countries confirmed that they resort to importation or use adapted formulations. The joint forces of European institutions and pharmaceutical industry are crucial for the development of paediatric formulations and contribute to better compliance and health outcomes.Keywords
This publication has 12 references indexed in Scilit:
- Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in EuropeEuropean Respiratory Journal, 2021
- Access to paediatric formulations for the treatment of childhood tuberculosisThe Lancet Child & Adolescent Health, 2020
- Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trialThe International Journal of Tuberculosis and Lung Disease, 2019
- The Roll-out of Child-friendly Fixed-dose Combination TB Formulations in High-TB-Burden Countries: A Case Study of STEP-TBJournal of Epidemiology and Global Health, 2019
- Compounded medication for patients with rare diseasesOrphanet Journal of Rare Diseases, 2018
- S2k-Leitlinie zur Diagnostik, Prävention und Therapie der Tuberkulose im Kindes- und JugendalterPneumologie, 2017
- Recomendaciones para la elaboración y administración de fármacos antituberculosos en niños. Segunda fase del Proyecto Magistral de la Red Española de Estudio de la Tuberculosis Pediátrica (pTBred)Anales de Pediatría, 2016
- The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosisEuropean Respiratory Journal, 2016
- El reto de la administración de antituberculosos en lactantes y preescolares. Proyecto Magistral de pTBredAnales de Pediatría, 2016
- Pediatric Tuberculosis: Global Overview and ChallengesClinical Infectious Diseases, 2010